Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study
Aims
Coronary microvascular dysfunction (CMD) represents a powerful independent predictor of adverse outcome in hypertrophic cardiomyopathy (HCM). No treatment for CMD exists. The angiotensin-converting enzyme (ACE)-inhibitor perindopril improves myocardial blood flow (MBF) in animal models of cardiac hypertrophy and in hypertensive patients. Whether HCM patients with CMD may benefit is unknown.
Methods
Fourteen HCM patients aged 18–60 years with CMD [MBF post 0.56 mg/kg dipyridamole (Dip) infusion
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Research letters Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Heart | Hypertrophic Cardiomyopathy | Study